Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by Cantor Fitzgerald

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They presently have a $8.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 58.42% from the company’s previous close.

A number of other analysts also recently weighed in on CAPR. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday, September 17th. Maxim Group restated a “buy” rating and set a $12.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, September 17th. Finally, Oppenheimer raised their target price on Capricor Therapeutics from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $20.00.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $5.05 on Friday. The business’s 50 day simple moving average is $4.37 and its 200 day simple moving average is $5.18. Capricor Therapeutics has a 1 year low of $2.68 and a 1 year high of $7.28. The company has a market capitalization of $161.49 million, a P/E ratio of -5.80 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. On average, sell-side analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new stake in shares of Capricor Therapeutics during the 1st quarter valued at $40,000. Main Street Financial Solutions LLC boosted its stake in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics during the second quarter worth about $147,000. Jump Financial LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $258,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares during the period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.